LINXS Co-Director. Principal investigator and Docent (Eng. Reader or Associate Professor) in Medical Protein Science, Faculty of Medicine. Moved to Lund University in 2009 after postdoctoral training at University of California and at Sahlgrenska Academy.
Jens Lagerstedt received his PhD in Biochemistry from Stockholm University in 2004, where after he did his first postdoctoral training at School of Medicine at University of California Davis, financed by, e.g., the Sweden-America foundation and NIH. At UCD he established his interest in the structure and function of apolipoproteins in health and disease. He returned to Sweden in 2007 to join the Center of Metabolic Research at Sahlgrenska in Göteborg to study the role of SNARE proteins in obesity and insulin resistance.
In 2008, Jens received an Assistant Professorship grant from the Swedish Research Council and moved in to the Medical Faculty at Lund University in 2009. There he is since then heading the Medical Protein Science group, and was in 2012 promoted to Docent (Eng. Reader or Associate Professor). In addition to leading his research group, Jens has been active as coordinator in the cross-faculty network MoReLife at Lund University with the aim to promote infrastructure and technology development in Life Science, including to promote interaction and exchange with the large-scale facilities MAX IV and ESS. He has together colleagues at the Science and Technology faculties at Lund University initiated the doctoral research school “Imaging of 3D structures” and he is director of the Summer Research Program at the Medical Faculty. Jens is also active at the Lund University Diabetes Center where he serves as co-director, and he is affiliated with pharma companies.
- Structure and function of apolipoprotein A-I in high-density lipoprotein; roles in cardiovascular disease and diabetes.
- Molecular and cellular mechanisms in disease-causing amyloidogenic apolipoproteins.
- Zinc-transporters in insulin-producing pancreatic beta cells. Structure and function of variants related to risk of type 2 diabetes and to autoimmunity in type 1 diabetes.